First Time Loading...

Novocure Ltd
NASDAQ:NVCR

Watchlist Manager
Novocure Ltd Logo
Novocure Ltd
NASDAQ:NVCR
Watchlist
Price: 12.03 USD -2.51%
Updated: Apr 25, 2024

Intrinsic Value

NVCR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. [ Read More ]

The intrinsic value of one NVCR stock under the Base Case scenario is 22.24 USD. Compared to the current market price of 12.03 USD, Novocure Ltd is Undervalued by 46%.

Key Points:
NVCR Intrinsic Value
Base Case
22.24 USD
Undervaluation 46%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Novocure Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NVCR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Novocure Ltd

Provide an overview of the primary business activities
of Novocure Ltd.

What unique competitive advantages
does Novocure Ltd hold over its rivals?

What risks and challenges
does Novocure Ltd face in the near future?

Has there been any significant insider trading activity
in Novocure Ltd recently?

Summarize the latest earnings call
of Novocure Ltd.

What significant events have occurred
in Novocure Ltd over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Novocure Ltd.

Provide P/S
for Novocure Ltd.

Provide P/E
for Novocure Ltd.

Provide P/OCF
for Novocure Ltd.

Provide P/FCFE
for Novocure Ltd.

Provide P/B
for Novocure Ltd.

Provide EV/S
for Novocure Ltd.

Provide EV/GP
for Novocure Ltd.

Provide EV/EBITDA
for Novocure Ltd.

Provide EV/EBIT
for Novocure Ltd.

Provide EV/OCF
for Novocure Ltd.

Provide EV/FCFF
for Novocure Ltd.

Provide EV/IC
for Novocure Ltd.

Show me price targets
for Novocure Ltd made by professional analysts.

What are the Revenue projections
for Novocure Ltd?

How accurate were the past Revenue estimates
for Novocure Ltd?

What are the Net Income projections
for Novocure Ltd?

How accurate were the past Net Income estimates
for Novocure Ltd?

What are the EPS projections
for Novocure Ltd?

How accurate were the past EPS estimates
for Novocure Ltd?

What are the EBIT projections
for Novocure Ltd?

How accurate were the past EBIT estimates
for Novocure Ltd?

Compare the revenue forecasts
for Novocure Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Novocure Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Novocure Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Novocure Ltd compared to its peers.

Compare the P/E ratios
of Novocure Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Novocure Ltd with its peers.

Analyze the financial leverage
of Novocure Ltd compared to its main competitors.

Show all profitability ratios
for Novocure Ltd.

Provide ROE
for Novocure Ltd.

Provide ROA
for Novocure Ltd.

Provide ROIC
for Novocure Ltd.

Provide ROCE
for Novocure Ltd.

Provide Gross Margin
for Novocure Ltd.

Provide Operating Margin
for Novocure Ltd.

Provide Net Margin
for Novocure Ltd.

Provide FCF Margin
for Novocure Ltd.

Show all solvency ratios
for Novocure Ltd.

Provide D/E Ratio
for Novocure Ltd.

Provide D/A Ratio
for Novocure Ltd.

Provide Interest Coverage Ratio
for Novocure Ltd.

Provide Altman Z-Score Ratio
for Novocure Ltd.

Provide Quick Ratio
for Novocure Ltd.

Provide Current Ratio
for Novocure Ltd.

Provide Cash Ratio
for Novocure Ltd.

What is the historical Revenue growth
over the last 5 years for Novocure Ltd?

What is the historical Net Income growth
over the last 5 years for Novocure Ltd?

What is the current Free Cash Flow
of Novocure Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Novocure Ltd.

Financials

Balance Sheet Decomposition
Novocure Ltd

Current Assets 1B
Cash & Short-Term Investments 910.6m
Receivables 83.9m
Other Current Assets 39.9m
Non-Current Assets 111.7m
PP&E 97.7m
Other Non-Current Assets 14m
Current Liabilities 179.1m
Accounts Payable 94.4m
Other Current Liabilities 84.7m
Non-Current Liabilities 604.5m
Long-Term Debt 568.8m
Other Non-Current Liabilities 35.7m
Efficiency

Earnings Waterfall
Novocure Ltd

Revenue
509.3m USD
Cost of Revenue
-128.3m USD
Gross Profit
381.1m USD
Operating Expenses
-613.9m USD
Operating Income
-232.9m USD
Other Expenses
25.8m USD
Net Income
-207m USD

Free Cash Flow Analysis
Novocure Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

NVCR Profitability Score
Profitability Due Diligence

Novocure Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Negative Free Cash Flow
Positive Revenue Growth Forecast
Positive 3-Years Revenue Growth
26/100
Profitability
Score

Novocure Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

NVCR Solvency Score
Solvency Due Diligence

Novocure Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Average D/E
37/100
Solvency
Score

Novocure Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NVCR Price Targets Summary
Novocure Ltd

Wall Street analysts forecast NVCR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NVCR is 27.88 USD with a low forecast of 15.15 USD and a high forecast of 44.1 USD.

Lowest
Price Target
15.15 USD
26% Upside
Average
Price Target
27.88 USD
132% Upside
Highest
Price Target
44.1 USD
267% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

NVCR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

NVCR Price
Novocure Ltd

1M 1M
-9%
6M 6M
-15%
1Y 1Y
-80%
3Y 3Y
-94%
5Y 5Y
-73%
10Y 10Y
-45%
Annual Price Range
12.03
52w Low
11.13
52w High
82.51
Price Metrics
Average Annual Return 28.74%
Standard Deviation of Annual Returns 74.21%
Max Drawdown -95%
Shares Statistics
Market Capitalization 1.3B USD
Shares Outstanding 107 093 000
Percentage of Shares Shorted 6.51%

NVCR Return Decomposition
Main factors of price return

What is price return decomposition?

NVCR News

Other Videos

Last Important Events
Novocure Ltd

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Novocure Ltd

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Novocure Ltd Logo
Novocure Ltd

Country

Jersey

Industry

Health Care

Market Cap

1.3B USD

Dividend Yield

0%

Description

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Contact

Saint Helier
No. 4 The Forum, Grenville Street
+441534756700.0
https://www.novocure.com/

IPO

2015-10-01

Employees

1 167

Officers

Executive Chairman
Mr. William F. Doyle
CEO & Director
Mr. Asaf Danziger
Chief Financial Officer
Ms. Ashley Cordova
Chief Operating Officer
Mr. Wilhelmus C. M. Groenhuysen
Executive VP & President of Novocure Oncology
Mr. Frank Leonard
Founder & CTO
Prof. Yoram Palti M.D., Ph.D.
Show More
Chief Science Officer
Dr. Moshe Giladi Ph.D.
VP of Investor Relations
Ms. Ingrid Goldberg
General Counsel
Mr. Barak Ben Arye
Chief Human Resources Officer
Mr. Michael Puri
Show Less

See Also

Discover More
What is the Intrinsic Value of one NVCR stock?

The intrinsic value of one NVCR stock under the Base Case scenario is 22.24 USD.

Is NVCR stock undervalued or overvalued?

Compared to the current market price of 12.03 USD, Novocure Ltd is Undervalued by 46%.